Study: Gene variant affects response to bowel cancer drugs

10/23/2008 | Bloomberg · Yahoo!

Advanced colon cancer patients with a mutation in the BRAF gene do not respond to ImClone Systems' Erbitux and Amgen's Vectibix, Italian researchers reported. The finding comes after earlier studies showed that another gene called KRAS can help identify patients who are most likely to benefit from both drugs.

View Full Article in:

Bloomberg · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX